Biotechnology Analysts Riley, Corwin & Minter, along with Tim Riley, PhD, discuss coverage and reimbursement expectations for cell and gene therapies in Europe, including Casgevy by VRTX/CRSP, Roctavian by BMRN and Zolgensma by NVS on an Analyst/Industry conference call to be held on January 4 at 10 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Vertex Pharmaceuticals named a ‘Catalyst Driven Idea’ at Morgan Stanley
- Charles River, Vertex reach important milestone in cell therapy collaboration
- Biotech Alert: Searches spiking for these stocks today
- Crispr Therapeutics positioned for European approval, says Piper Sandler